Radiopharmaceutical developer FluoroPharma Medical said that a phase II trial of its F-18 tetraphenylphosphonium (TPP) BFPET agent for measuring cardiovascular blood flow will be performed at Massachusetts General Hospital (MGH).
BFPET is an F-18-labeled tracer designed to enter myocardial cells in direct proportion to blood flow and cell membrane potential, according to the firm. BFPET has been designed to differentiate between cells of the myocardium that may be ischemic and cells that are healthy.
The tracer has the potential to produce clear images with increased resolution, and its improved sensitivity will offer clinicians earlier and more accurate information for effective patient management, the company said.
